SEPTIN9 and rectal cancer: Septin 9 methylation could be useful as an epigenetic biomarker to confirm a complete clinical response following neoadjuvant therapy in locally advanced rectal cancer, especially when adapted to a non-surgical “watch and wait” protocol [18].